21 filings
8-K
FGEN
FibroGen Inc
23 Dec 19
Fibrogen Submits New Drug Application to the U.S. Fda for Roxadustat In Patients with Anemia of Chronic Kidney Disease
9:06am
8-K
FGEN
FibroGen Inc
16 Dec 19
Departure of Directors or Certain Officers
12:00am
8-K
FGEN
FibroGen Inc
2 Dec 19
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
7:10am
8-K
FGEN
FibroGen Inc
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
FGEN
FibroGen Inc
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
app3jwc xufw
8 Nov 19
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
2:00pm
8-K
rx8kxi3rzrlg8b34oi
11 Oct 19
Regulation FD Disclosure
11:49am
8-K
u0gvp4z d9
9 Oct 19
Departure of Directors or Certain Officers
5:14pm
8-K
ki07d977t1x
26 Sep 19
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment
9:01am
8-K
a65584m
20 Sep 19
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
9:00am
8-K
vlv5apg
26 Aug 19
Departure of Directors or Certain Officers
9:04am
8-K
iwa1ea7
21 Aug 19
Roxadustat Approved In China for Treatment of Anemia In Chronic Kidney Disease Patients Not Receiving Dialysis
4:39pm
8-K
znvs jnj58
8 Aug 19
Fibrogen Reports Second Quarter 2019 Financial Results
4:15pm
8-K
phi j12ft12fm6j5h3h7
24 Jul 19
Other Events
9:46pm
8-K
g197ck3 2jp3m3ypue
22 Jul 19
Other Events
8:00am
8-K
qb4yuj142sl311bcpc
28 Jun 19
Regulation FD Disclosure
9:01am
8-K
n7335lu xl
5 Jun 19
Fibrogen Appoints Suzanne Blaug to Board of Directors
5:15pm
8-K
qgwu494 7m9haaa
9 May 19
Fibrogen Reports First Quarter 2019 Financial Results
4:15pm
8-K
a03vp3pp8915xyb ut
15 Apr 19
Other Events
9:00am
8-K
8kq4grxoxa
27 Feb 19
Fibrogen Reports Fourth Quarter and Full Year 2018 Financial Results
12:00am